NCT06941376招募中2 期
Pragmatic, Open-Label, Two-Stage, Pilot Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Efficacy of the study drugs for the treatment of relapsing polychondritis.
研究概览
简要总结
Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).
详细描述
Twenty eligible patients with mild to moderately active RP within 60 days prior to screening will be enrolled to the study.
Subjects will be eligible to enroll into stage 1 if they are naïve to methotrexate (MTX) or azathioprine (AZA), or having active disease on MTX or AZA for 8 weeks or less. Patients naïve to MTX and AZA will be started on MTX. AZA will be started if there is a contraindication to MTX. Patients on MTX/AZA for 8 weeks or less with active disease will be continued with the respective medication.
Patients who do not meet primary effectiveness end point in Stage 1 or develop relapse of RP or intolerance to MTX/AZA will move to Stage 2.
Patients eligible to be enrolled to Stage 2 directly
- History of intolerance or side effects to MTX or AZA with active disease
- Currently on MTX or AZA for at least 8 weeks or has received it within the past 60 days for at least 8 weeks and still has mild/ moderate active disease
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A. ≥18 years of age
- •B. Must fulfill McAdam's or Damiani's or Michet's Criteria Diagnostic Criteria for Relapsing Polychondritis McAdam's Criteria (1976)
- •≥ 3 criteria out of 6 of the following:
- •Bilateral auricular chondritis
- •Non-erosive seronegative polyarthritis
- •Nasal chondritis
- •Ocular inflammation
- •Respiratory tract chondritis
- •Cochlear and/or vestibular dysfunction
- •Damiani's Criteria (1979)
- •≥3 of McAdam's Criteria as above
- •≥1 of McAdam's Criteria with histological confirmation of chondritis
- •≥2 of McAdam's Criteria with positive response to glucocorticoids or dapsone
- •Michet's Criteria (1986)
- •Presence of ≥2 of the following criteria:
- •Auricular chondritis
- •Nasal chondritis
- •Laryngotracheal chondritis
- •Or presence of ≥1 of the above criteria and ≥2 of the following criteria
- •Seronegative inflammatory arthritis
- •Ocular inflammation
- •Hearing loss
- •Vestibular dysfunction
- •C. Mild to moderately active disease within 60 days prior to screening where the symptoms cannot be attributed to any cause other than RP and which, in the investigator's opinion, requires addition/ increase in prednisone dose between 15-60 mg/ day.
- •At the time of enrollment and during the trial, the following symptoms of active disease which will be evaluated:
- •Auricular inflammation: defined as increase/ new onset pain/ swelling/redness of external ear(s), ear canal
- •Nasal inflammation: defined as increase/ new onset pain/ swelling/redness of external nose
- •Ocular inflammation: defined as new onset/ worsening unilateral/ bilateral episcleritis/scleritis/ uveitis.
- •Inflammatory arthritis: defined as new onset/ worsening morning stiffness≥30 minutes, physician diagnosed tenderness/swelling in ≥1 joint; new onset/ worsening costochondritis.
- •Mild to moderate airway inflammation: defined as new onset/ worsening mild to moderate inflammation of upper airway diagnosed by direct laryngoscopy and attributed to RP; abnormal CT airway/ bronchoscopy showing wall thickening of airway (larynx, trachea, bronchi) and absence of severe manifestations such as new onset SGS/tracheomalacia/ bronchomalacia.
- •Sinonasal disease: defined as new onset/ increase in nasal crusting, discharge bleeding
- •Constitutional symptoms: defined as new onset/ worsening fever, unintentional weight loss of ≥ 5% of body weight, night sweats Patients must have at least 1 of the first 5 criteria within the past 60 days prior to the enrollment.
- •D. Willing and able to comply with treatment and follow-up procedures.
- •E. Both men and women of childbearing potential must be willing to use an effective means of birth control while receiving treatment throughout the study. Effective contraception methods include abstinence, oral contraceptives (birth control pills), intra-uterine-device, diaphragm, approved hormone injections, condoms, or medical sterilization.
- •F. Willing and able to provide written informed consent.
排除标准
- •A. Severe disease manifestations within the past 14 days requiring hospitalization, and/or intravenous pulsed dose glucocorticoid treatment for disease control.
- •B. Prior exposure of 4 weeks or longer to adalimumab, infliximab, and/or tocilizumab.
- •C. Prior exposure to >2 biologics and/or JAKi.
- •D. Evidence of active infection.
- •E. Known infection with human immunodeficiency virus (HIV), untreated hepatitis C infection, or a positive hepatitis B virus surface antigen.
- •F. Patients at risk for tuberculosis (TB) defined as follows:
- •Current clinical, radiographic or laboratory evidence of active TB, even if currently being treated. Chest x-rays (posterior/anterior and lateral) obtained within the 6 months prior to screening and TB testing (IFN gamma release assay or PPD) performed in the past month prior to screening will be accepted; however, a copy of the reports must be placed in the participant binder.
- •A history of active TB unless there is documentation that the patient had received prior anti-TB treatment that was appropriate in duration and type according to local health authority guidelines.
- •Patients with a positive TB screening test indicative of latent TB will not be eligible for the study unless they: i. Have no evidence of current TB based on chest x-ray performed during the screening period and by history and physical exam, and ii. They are currently being treated for latent TB or the site has documentation of successful prior treatment of latent TB. Treatment regimens should be dictated by local guidelines as long as the treatment dose and duration meet or exceed local health authority guidelines. Patients with latent TB may be eligible for the trial prior to completion of treatment as long as they have completed at least 4 weeks of treatment and they have no evidence of current TB on chest x-ray at screening.
- •G. Inability to comply with study guidelines.
- •H. Cytopenia: platelet count <80,000/mm3, absolute neutrophil count <1500/mm3, hematocrit < 20%.
- •I. Other uncontrolled disease (co-morbidity) that could prevent a subject from fulfilling the study requirements or that would increase the risk of study procedures.
- •J. Patients who have a present malignancy or previous malignancy within the last 5 years prior to screening (except documented history of cured non-metastatic squamous or basal cell skin carcinoma or cervical carcinoma in situ). Patients who had a screening procedure that is suspicious for malignancy, and in whom the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory or other diagnostic evaluations.
- •K. Receipt of an investigational agent or device within 30 days prior to enrollment
- •L. A live vaccination < 4 weeks before enrollment
- •M. Presence of any of the following diseases:
- •ANCA-associated vasculitis
- •Polyarteritis nodosa
- •Giant cell arteritis
- •Takayasu's arteritis
- •Cogan's syndrome
- •Tuberculosis or atypical mycobacterial infections
- •Deep fungal infections
- •Lymphoma, lymphomatoid granulomatosis, or other type of malignancy that mimics vasculitis
- •Overlap with other systemic autoimmune diseases which would impair assessment of response
- •Diagnosis of VEXAS syndrome
研究组 & 干预措施
Adalimumab, Infliximab, or Tocilizumab
Experimental
干预措施: Tocilizumab (Biological)
Azathioprine or Methotrexate
Experimental
干预措施: Methotrexate (MTX) (Drug)
Azathioprine or Methotrexate
Experimental
干预措施: Azathioprine (AZA) (Drug)
Adalimumab, Infliximab, or Tocilizumab
Experimental
干预措施: Adalimumab (Biological)
Adalimumab, Infliximab, or Tocilizumab
Experimental
干预措施: Infliximab (Biological)
结局指标
主要结局
Efficacy of the study drugs for the treatment of relapsing polychondritis.
时间窗: 26 weeks
The proportion of subjects in remission at week 26
次要结局
- Physician's global assessment of response(Assessed at weeks 0, 12, and 26)
- Response rates for each of the study drugs(Response evaluated weeks 12 and 26)
- Patient's global assessment of response(Assessed at weeks 0, 12, and 26)
- Health-related quality of life(Assessed at weeks 0, 12, and 26)
- Time to disease flare(26 weeks)
- Safety of study drugs in RP(26 weeks)
研究者
Shubhasree Banerjee
Assistant Professor of Clinical Medicine
University of Pennsylvania
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A 48 Week Study to Evaluate the Efficacy and Safety of Two (2) EYS606 Treatment Regimens in Subjects With Active Chronic Non-infectious Uveitis (CNIU)Non-infectious UveitisNCT04207983Eyevensys3
已完成
2 期
Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast CancerNeoplasm MetastasisBreast CancerNCT00377559Catharina Ziekenhuis Eindhoven70
已完成
2 期
A Study of Different Formulations of the L-PPDS in Subjects With OH or OAGGlaucomaOcular HypertensionNCT00967811Mati Therapeutics Inc.83
撤回
2 期
PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System LymphomaPrimary Central Nervous System LymphomaNCT03120000PIQUR Therapeutics AG
已完成
2 期
PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System LymphomaPrimary Central Nervous System LymphomaNCT02669511PIQUR Therapeutics AG21